ClinicalTrials.gg
RecruitingNCT06026267Updated Aug 9, 2024

Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis

An interventional study of 20% High Dose Albumin and Standard Medical Treatment in Liver Cirrhosis and Spontaneous Bacterial Peritonitis, sponsored by Institute of Liver and Biliary Sciences, India. Recruiting at 1 site in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Institute of Liver and Biliary Sciences, India · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India — 15 open to participants now, 15 under way, 1 of them phase 3. Liver Cirrhosis · Institute of Liver and Biliary Sciences, India.

Planned enrollment
6th of 42
300 · median 100
Started
2023
with 11 others
No phase
40 of 53
12 open now
Primary completion
2024-12
later than 4 of 14 live
Registered
36th of 53
by date

Among the 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India, this one is the 6th largest by planned enrollment of the 42 interventional ones that give a count, is one of 12 that started in 2023, is one of 40 with no phase, reaches primary completion later than 4 of the 14 other live ones, and was the 36th registered.

Liver Cirrhosis

1,302 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

15 of the 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Liver Cirrhosis by Institute of Liver and Biliary Sciences, India, or all of them as a file.
02

Study summary

The role of Albumin in prevention and Treatment of Acute Kidney Injury (AKI) in patients with Spontaneous Bacterial Peritonitis (SBP) who are at high risk of AKI development has been clearly defined, which decreases the morbidity and mortality. However the conventional dose recommended by the guidelines is usually not tolerated by the Indian population. Investigator propose that the low dose is as beneficial as the standard dose in patients with high risk SBP in the prevention/progression of renal dysfunction in cirrhotic patients with high risk spontaneous bacterial peritonitis. If confirmed, these results could support a significant cost reduction in the management of ascites in cirrhotic patients and decrease the side effects of the volume overload in the patient of the cirrhosis.

Read the detailed description

Hypothesis Alternate Hypothesis: Low dose albumin is as effective as conventional dose albumin in cirrhosis with high risk SBP patients having AKI development or progression by day 4.

Aim:-To compare the efficacy and safety of low dose albumin with conventional dose albumin in AKI development or progression in patients with cirrhosis and high risk spontaneous bacterial peritonitis.

Study population: Patients of age > 18 years of age with cirrhosis of liver who are admitted in ward/ICU diagnosed with high risk SBP.

Study design: Randomized controlled trial Study period:1.5year Sample size: 300 (150 cases in each group) Assuming that the rate of AKI development in conventional dose albumin group - 10% and low dose albumin group 15%, Power- 80%, Alpha- 10% ONE SIDED, Non inferiority limit- 5, cases needed to enroll are 270, further assuming 10% dropout, investigator decided to enroll total 300 cases, randomly allocated with 150 cases in each arm by block randomization method with Block size of 10 Cases will be randomly allocated in 2 groups by block randomization method with block size taken as 10.

STATISTICAL ANALYSIS:

Continuous variables- Mean +/- SD Categorical variables as percentages (%) or Frequencies Student t test will be applied in continuous data compared with two groups Survival analysis like Cox-Regression model and Kaplan-Meir plots will be plotted to find the possible factors responsible for mortality Besides these, Intent to treat (ITT) and Per Protocol (PP) will be done at the time of data analysis.

Adverse effects:

Patients receiving Albumin may experience Nausea, Vomiting, Fever with chills, dyspnea Wheezing, Volume overload, Anaphylactic reaction

Stopping rule of study:

Adverse reaction to drug Cardiopulmonary compromise

03

Conditions studied

  • Liver Cirrhosis
  • Spontaneous Bacterial Peritonitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18years
  2. Cirrhosis with SBP (community acquired /Health care associated/ nosocomial)
  3. High risk SBP : Patients with S Bil >4 mg/dL and/or s creat > 1 mg/dl at presentation

Exclusion criteria

Exclusion Criteria:

  1. Antibiotic treatment within one week before the diagnosis of SBP (except for prophylactic treatment with norfloxacin)
  2. Significant cardiac failure, pulmonary disease
  3. Known CKD or findings suggestive of organic nephropathy (proteinuria, haematuria, or abnormal findings on renal USG)
  4. Hepatocellular carcinoma
  5. infection
  6. GI bleed within 1 month before the study
  7. Grade 3 to 4 hepatic encephalopathy
  8. Shock (MAP \< 65)
  9. Serum creatinine level of > 3 mg/decilitre
  10. Presence of any potential causes of dehydration (such as diarrhea or an intense response to diuretic treatment within one week before the diagnosis of SBP).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    High Dose Arm+Standard Medical therapy

    Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg body weight (Maximum 100g)on day 3 along with standard medical therapy.

    Biological: 20% High Dose Albumin · Other: Standard Medical Treatment

  • Experimental
    Reduced Dose Albumin+Standard Medical therapy

    Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy.

    Other: Standard Medical Treatment · Biological: 20% Reduced Dose Albumin

Interventions

  • A\]. Patients in the conventional albumin Arm will receive Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg bodyweight (Maximum 100g)on day 3 along with standard medical therapy. Duration of albumin over 24 hours.

  • OtherStandard Medical Treatment

    Standard Medical Treatment

  • Biological20% Reduced Dose Albumin

    B\]. Patients in the low dose albumin Arm will receive Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy. Duration of albumin over 24 hours.

06

What researchers measure

Primary outcomes

  1. Proportion of patients developing new AKI or having progression of AKI by day 4.

    Time frame: Day 4

Secondary outcomes

  1. Resolution of Spontaneous Bacterial Peritonitis by day 5

    Resolution is defined as decrease in ascitic fluid PMN \> 25% from baseline

    Time frame: Day 5

  2. Change on Serum Ascites Albumin Gradient (SAAG) in both the groups.

    Time frame: Day 5

  3. Change in cell count (PMN) in both groups.

    Time frame: Day 5

  4. Changes in PRA levels from baseline to day 7

    Time frame: day 7

  5. Changes in TNF-alpha levels from baseline to day 7

    Time frame: day 7

  6. Changes in IL-6 levels from baseline to day 7

    Time frame: day 7

  7. Changes in endotoxin levels from baseline to day 7

    Time frame: day 7

  8. Changes in renal resistive index from baseline to day 7

    Time frame: day 7

  9. Number of patients with development of complications in both groups

    Time frame: 90 days

  10. Number of Participants with changes in ProBNP from baseline to day 4 or if shortness of breath occurs

    Time frame: Day 4

  11. Number of Participants with changes in vWF-Ag from baseline to day 4

    Time frame: Day 4

  12. Number of patients expired in both the groups

    Time frame: Day 7

  13. Number of patients expired in both the groups

    Time frame: Day 28

  14. Number of patients expired in both the groups

    Time frame: Day 90

  15. Duration of hospital stay

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2024, 14 months after the start.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 14 months is below that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Sep 7, 2023
StartActual
Oct 10, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06026267
Responsible party
Sponsor
First posted
Sep 7, 2023
Start date
Oct 10, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Aug 9, 2024

Study contacts

Dr Saurav Paul, MD
Contact
saurav.paul79@gmail.com
01146300000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion